Diabetes Care:空腹胰岛素降低或与腰围和体质指数轻微增加相关

2012-06-09 张一宸译 医学论坛网

  日本一项研究分析了2000年~2009年日本初诊2型糖尿病(T2DM)患者空腹胰岛素水平与代谢性危险因素之间的关系。结果表明,T2DM患者空腹胰岛素水平降低与腰围(WC)/体质指数(BMI)轻微增加相关。该研究6月4日在线发表于《糖尿病护理》(Diabetes Care)杂志。  研究纳入日本4798例初诊T2DM患者,患者基线空腹胰岛素水平和常规临床检测项目由日本糖尿病临床数据管理

  日本一项研究分析了2000年~2009年日本初诊2型糖尿病(T2DM)患者空腹胰岛素水平与代谢性危险因素之间的关系。结果表明,T2DM患者空腹胰岛素水平降低与腰围(WC)/体质指数(BMI)轻微增加相关。该研究6月4日在线发表于《糖尿病护理》(Diabetes Care)杂志。  研究纳入日本4798例初诊T2DM患者,患者基线空腹胰岛素水平和常规临床检测项目由日本糖尿病临床数据管理研究组(JDDM)连续收集2年。研究采用多元系数回归分析方法,通过多个临床自变量评估因变量空腹胰岛素水平数值。  结果显示,2000年至2009年研究对象空腹胰岛素水平降低,多元线性回归分析发现:T2DM患者WC、BMI、平均血压、甘油三酯、高密度脂蛋白(HDL)胆固醇与空腹胰岛素水平相关,其中相关性最大的是WC和BMI。经年龄和空腹血糖校正后,协方差分析(ANCOVA)清楚证明T2DM患者空腹胰岛素水平降低与BMI增加相关。

  链接:

  Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]
    2012-06-12 baoya
  4. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]
    2012-06-11 naiwu77
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759145, encodeId=85891e5914535, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Jan 29 12:18:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636512, encodeId=158c163651209, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed May 01 17:18:00 CST 2013, time=2013-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749348, encodeId=5b421e49348d9, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Tue Jun 12 22:18:00 CST 2012, time=2012-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900955, encodeId=50ce1900955d0, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Jul 24 16:18:00 CST 2012, time=2012-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308115, encodeId=7fb113081159a, content=<a href='/topic/show?id=8f0085426a7' target=_blank style='color:#2F92EE;'>#腰围#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85426, encryptionId=8f0085426a7, topicName=腰围)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457209, encodeId=7729145e2097b, content=<a href='/topic/show?id=e936266e7a4' target=_blank style='color:#2F92EE;'>#体质指数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26677, encryptionId=e936266e7a4, topicName=体质指数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41e05859443, createdName=tigerlr100, createdTime=Mon Jun 11 13:18:00 CST 2012, time=2012-06-11, status=1, ipAttribution=)]

相关资讯

Blood:治疗慢性疾病和糖尿病伤口的新药物

近日,瑞典Ume?大学开发出了一个独特的新药物,该药物可以启动和加快糖尿病和其他慢性疾病的伤口愈合。这一药物是经过几年的实验研究而获得成功的,目前正准备进行临床试验。研究人员证实纤维蛋白溶酶原是一个触发炎症反应的启动和加速伤口愈合的关键调节因子,相关研究论文发表在Blood杂志上。 纤溶酶是一个众所周知的血浆蛋白,主要在肝脏中产生,在所有体液中都存在。Ume?研究人员现在重新评估纤溶酶的作用,揭

利拉利汀对非裔2型糖尿病患者安全有效

费城(EGMN)——一项纳入226例非裔2型糖尿病患者的多中心、随机、安慰剂对照试验显示,利拉利汀治疗与高血糖显著改善相关。    “非裔美国人一生中发生糖尿病的可能性增加77%,并且在临床试验中对降糖药物应答不佳,”美国小石城阿肯色糖尿病与内分泌中心的医学研究主管James R. Thrasher博士在美国临床内分泌医师协会年会上介绍,利拉利汀是一种每日用药1次的二肽基肽

AACE 2012:Resolute支架在糖尿病患者中的性能优

   在第21届美国临床内分泌医师协会年会(AACE2012, 5月23~27日, 美国费城)提交的一项新研究报告称,非胰岛素依赖型糖尿病患者置入Resolute佐他莫司洗脱冠脉支架2年后的安全性和功能预后与置入该支架的非糖尿病患者相似。此外,置入Resolute支架的胰岛素依赖型糖尿病患者的预后优于文献报道的置入其他药物洗脱支架(DES)的糖尿病患者。   今年3月,美国食品药品管理

Pharmacotherapy:老年和肾病患者应用磺脲类低血糖风险高

  美国一项巢式病例对照研究报告,在应用磺脲类的住院糖尿病患者中,高龄、肾小球滤过率低以及同时应用中长效胰岛素治疗者发生低血糖的风险高。研究5月8日在线发表于《药物治疗》(Pharmacotherapy)。   该研究纳入117例糖尿病住院患者和相同数量对照者。结果为,19%应用磺脲类治疗的患者至少经历1次低血糖事件,服用格列本脲、格列美脲和格列吡嗪者中分别有22%、19%和16%有低血糖发作。

Diabetes Care:二甲双胍联合利拉鲁肽+胰岛素序贯方案治疗2型糖尿病

  一项多国研究报告,在二甲双胍治疗血糖控制不佳的2型糖尿病患者中,序贯加用利拉鲁肽和地特胰岛素的强化治疗方案可被多数患者耐受,患者血糖控制佳、体重持续减轻且低血糖发生率低。研究5月14日在线发表于《糖尿病护理》(Diabetes Care)。   该研究纳入988例二甲双胍治疗血糖控制不佳的2型糖尿病患者,加用利拉鲁肽1.8mg/d治疗12周(导入期)后糖化血红蛋白(HbA1c)仍≥7%的患者

Diabetes Care:严重低血糖不增加1型糖尿病心血管风险

  欧洲一项EURODIAB前瞻性并发症研究结果提示,在1型糖尿病患者中,严重低血糖并不增加心血管疾病(CVD)风险。《糖尿病护理》(Diabetes Care)2012年5月14日在线刊登。   该研究纳入2181例1型糖尿病患者,调查严重低血糖发生情况并评估随访7.3年期间CVD发病情况。其中531例患者被纳入巢式病例对照研究,分为并发症组(363例)和无并发症的对照组(168例),接受炎症